Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Originally published as Ann Surg Oncol Early Release 10.1245/ASO.2004.09.002 on May 18, 2004

Annals of Surgical Oncology 11:629-635 (2004)
© 2004 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dicken, B.J.
Right arrow Articles by Hamilton, S.M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dicken, B.J.
Right arrow Articles by Hamilton, S.M.

ORIGINAL ARTICLES

Gastric Cancer: Establishing Predictors of Biologic Behavior with Use of Population-Based Data

B.J. Dicken, MD, L.D. Saunders, PhD, G.S. Jhangri, MSc, C. de Gara, FRCSC, C. Cass, PhD, S. Andrews, MD and S.M. Hamilton, FRCSC

From the Departments of Surgery (BJD, CdeG, SMH), Public Health Sciences (LDS, GSJ), Laboratory Medicine and Pathology (SA), and Oncology (CC), University of Alberta and Cross Cancer Institute, Edmonton, Alberta, Canada.

Correspondence: Address correspondence and reprint requests to: Dr. S. M. Hamilton, 2D2 Walter C. Mackenzie Health Sciences Center, 8440-112 St. University of Alberta Hospital, Edmonton, Alberta, Canada T6G 2B7; Fax: 780-407-7394; e-mail: shamilto{at}cha.ab.ca

Background: Tumor thickness and nodal status are important predictors of survival following curative resection for gastric cancer. Lymphovascular invasion (LVI) is a potential predictor of biological behavior. The relationship between LVI and tumor thickness (T status) has not been established in population-based studies.

Methods: Clinicopathological and survival data of 577 patients at nine centers, from between 1991 and 1997, was collected from patient records and a Provincial Cancer Registry. The primary endpoint of the study was death. A secondary analysis of a node-negative subgroup examined the significance of LVI with respect to T status.

Results: The population disease-specific survival was 28%. In a multivariate analysis, T, N, M, esophageal margin, tumor morphology, and residual tumor category were independent predictors of survival. LVI was documented in 58% of resected tumors. LVI correlated with advancing T and N status but was not significant in a multivariate population model. Subgroup analysis of node-negative gastric cancer found T status and LVI to be independent predictors of survival. LVI was associated with a 5-year survival of 8%, versus 43% among patients in whom it was absent (P < .001).

Conclusions: T status and N status were the most important independent predictors of survival in a population-based study of gastric cancer. LVI correlated with advancing N and T status. Multivariate analysis of node-negative patients showed LVI and T status are independent predictors of survival.

Key Words: Adenocarcinoma • Neoplasm invasiveness • Prognosis • Stomach neoplasm • Survival analysis




This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
J. E. Gervasoni Jr., S. Sbayi, and B. Cady
Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data.
Ann. Surg. Oncol., September 1, 2007; 14(9): 2443 - 2462.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. Rocken, F.-W. Rohl, E. Diebler, U. Lendeckel, M. Pross, S. Carl-McGrath, and M. P.A. Ebert
The Angiotensin II/Angiotensin II Receptor System Correlates with Nodal Spread in Intestinal Type Gastric Cancer
Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1206 - 1212.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Society of Surgical Oncology.